Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Terns Pharmaceuticals (TERN)
NASDAQ:TERN
Holding TERN?
Track your performance easily
TERN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.26 - $11.40
Previous Close$8.96
Volume2.17M
Average Volume (3M)1.88M
Market Cap
$794.54M
Enterprise Value$531.08M
Total Cash (Recent Filing)$225.30M
Total Debt (Recent Filing)$249.00K
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Nov 06, 2024EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding70,371,911
10 Day Avg. Volume5,498,149
30 Day Avg. Volume1,879,550
Standard Deviation0.30
R-Squared0.00394
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.80
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.20
Forecast
1Y Price Target
$19.80Price Target Upside110.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Terns Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsTERN-601 demonstrated significant weight-loss efficacy in obese or overweight patients, positioning it at the upper region of the oral obesity field.
Market PositionTerns Pharmaceuticals is entering the obesity field with promising PoC data from a first-in-human, 28-day, Phase I study of its lead oral, small-molecule, GLP-1 receptor agonist, potentially driving significant value.
Safety ProfileThere were zero Grade 3+ adverse events and zero patients discontinued treatment during the 28-day study, indicating an excellent safety profile for TERN-601.
Bears Say
Clinical Trial ResultsZealand Pharmaceuticals announced what was viewed to be disappointing Phase 2 data for dapiglutide.
Financial PerformanceTERN reported 2Q24 net loss of $22.7M.
Management ChangesAs part of the ongoing changes to the management team following the arrival of the company's new CEO in February, Bryan Yoon (COO) and Mark Vignola (CFO) will leave TERN in an orderly fashion (CFO will remain until 2025).
---
Ownership Overview
22.79% Insiders
12.71% Mutual Funds
53.10% Other Institutional Investors
11.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TERN FAQ
What was Terns Pharmaceuticals’s price range in the past 12 months?
Terns Pharmaceuticals lowest stock price was $3.26 and its highest was $11.40 in the past 12 months.
What is Terns Pharmaceuticals’s market cap?
Currently, no data Available
When is Terns Pharmaceuticals’s upcoming earnings report date?
Terns Pharmaceuticals’s upcoming earnings report date is Nov 06, 2024 which is in 50 days.
How were Terns Pharmaceuticals’s earnings last quarter?
Terns Pharmaceuticals released its earnings results on Aug 05, 2024. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.339 by $0.029.
Is Terns Pharmaceuticals overvalued?
According to Wall Street analysts Terns Pharmaceuticals’s price is currently Undervalued.
Does Terns Pharmaceuticals pay dividends?
Terns Pharmaceuticals does not currently pay dividends.
What is Terns Pharmaceuticals’s EPS estimate?
Terns Pharmaceuticals’s EPS estimate is -$0.34.
How many shares outstanding does Terns Pharmaceuticals have?
Terns Pharmaceuticals has 84,435,960 shares outstanding.
What happened to Terns Pharmaceuticals’s price movement after its last earnings report?
Terns Pharmaceuticals reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.339. Following the earnings report the stock price went down -2.599%.
Which hedge fund is a major shareholder of Terns Pharmaceuticals?
Among the largest hedge funds holding Terns Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds Terns Pharmaceuticals’s shares valued at 7M.
---
Terns Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.80 (110.41% Upside)
$19.80 (110.41% Upside)
Blogger Sentiment
Bullish
TERN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 572.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.2%
Last 30 Days ▲ 31.3%
Last 30 Days ▲ 31.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
74.90%
12-Months-Change
Fundamentals
Return on Equity
-38.92%
Trailing 12-Months
Asset Growth
-20.30%
Trailing 12-Months
Company Description
Terns Pharmaceuticals
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
---
TERN Stock 12 Month Forecast
Average Price Target
$19.80
▲(110.41% Upside)
Technical Analysis
Best Analysts Covering TERN
1 Year
1 Year Success Rate
13/17 ratings generated profit
1 Year Average Return
+23.35%
reiterated a buy rating 7 days ago
Copying Graig Suvannavejh's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +23.35% per trade.
---